Coleman Blaise 4

What Happened
Coleman Blaise, a director of Ocugen, Inc. (OCGN), received a grant of a derivative equity award covering 170,100 shares on June 11, 2026. The filing reports an acquisition price of $0.00 (total reported cash outlay $0). This is an award/grant (not a purchase or sale) and is subject to vesting conditions.

Key Details

• Transaction type: Award/Grant (derivative) reported on Form 4 (code A).
• Transaction date: June 11, 2026; Form 4 filed June 15, 2026 (filed within the required two business days).
• Shares involved: 170,100 shares; reported price $0.00 (reported value $0).
• Vesting: The award vests upon the earlier of (a) June 11, 2027 or (b) Ocugen’s next annual meeting of stockholders, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax withholding, or sale noted in this filing.

Context
This entry represents a compensation-related equity award to a director, common for board service. Because the award is subject to future vesting and was not purchased or sold, it does not represent an immediate market trade — it’s a potential future stake if vesting and any further terms are satisfied.